Oct 12th 2012 - Edison Investment Research today published a report on Scancell Holdings (SCLP.L, LSE:SCLP, LON:SCLP) entitled "An Important Year Ahead". In summary, the report says:
Scancell has exploded onto the UK biotech scene this year, with a dramatic 900% share price rise following rising awareness of its lead compound, the SCIB1 anti-cancer vaccine, which is undergoing Phase II trials. Understandably, investors have taken profits as the company reported FY12 results. Scancell appears to be well funded (with cash of £3.5m at April 2012) through to the important Phase II trials results for SCIB1, due for completion by end 2013.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »